石药创新向港交所递交上市申请，中信证券为其独家保荐人。该公司业务涵盖生物制药、功能性原料及 保健食品。 2016年将主营业务扩展至保健食品行业，推出丰富且全面的保健食品组合，果维康商标已被认定为中国 驰名商标，销售网络覆盖全国近200家连锁药房。2022年收购石药圣雪100%的股权，将产品类型扩展至 其他功能性原料，如阿卡波糖和无水葡萄糖。 全球及中国医药市场均呈现显著增长，并预计在未来十年保持快速增长。全球抗肿瘤药物市场、抗体药 物市场以及中国相关市场均呈现强劲增长趋势，特别是中国的ADC市场预计将从2024年的人民币39亿 元显著扩大至2035年的人民币1586亿元。 专注于差异化靶点的多技术路径创新疗法开发，重点布局存在重大未满足临床需求且增长潜力显著的疾 病领域，包括肿瘤、自身免疫性疾病和感染性疾病等。2024年下半年，实现两款抗体药物的商业化，1 类创新药恩舒幸(抗PD-1单抗)以及中国首个奥马珠单抗生物类似药恩益坦。在mRNA疫苗领域，度恩泰 及度恩泰2已于2023年在中国被纳入紧急使用。截至2025年12月1日，拥有15个处于临床或后期开发阶段 的在研药物，其中包括9款ADC在研药物和1款mRN ...

Core Viewpoint - InnoCare Pharma-B (09606) is planning to list on the STAR Market, pending market conditions and further approvals from the board and shareholders, following a successful IPO on the Hong Kong Stock Exchange that raised over HKD 1.5 billion [1] Group 1: Company Developments - InnoCare Pharma's stock price increased by 5% in early trading, reaching HKD 345.6 with a trading volume of HKD 599 million [1] - The company was listed on the Hong Kong Stock Exchange on April 15, raising over HKD 1.5 billion, marking it as one of the largest IPOs in the Hong Kong 18A sector in the past four years [1] - The stock price peaked at HKD 563.5 in September, reflecting a maximum increase of 495.67% from the IPO price of HKD 94.6 per share [1] Group 2: Industry Insights - According to a report by CICC, the global ADC market is projected to reach approximately USD 10.4 billion in 2023 and is expected to grow to USD 115.1 billion by 2032 [1] - InnoCare Pharma plans to submit applications for its DB-1303 (HER2 ADC) for endometrial cancer in the U.S. and for breast cancer in China by 2025 [1] - The company’s DB-1311 (B7-H3 ADC) shows potential as a best-in-class candidate for prostate cancer, while DB-1310 (HER3 ADC) is expected to follow suit; DB-1305 (TROP2 ADC) and dual antibody explorations are leading globally in next-generation ADC research [1]